Table 1.

Key features of the Tuberculosis Trials Consortium clinical trials included in this analysis

Trial	Study Population	Intervention Evaluated	Time of Enrollment	Timing of Study Visits at which Symptoms Were Assessed	Primary Endpoint	Duration of Follow-up
Study 22 (11, 12)	Pulmonary TB, susceptible to INH and RIF	Once-weekly rifapentine plus INH vs. twice-weekly rifampin plus INH in the continuation phase	2 mo (end of the intensive phase of therapy)	Time of TB diagnosis (retrospectively); monthly during Months 2–6 of treatment, then at 3, 6, 9, 12, 18, and 24 mo after completing treatment	Culture-positive treatment failure or recurrent TB	24 mo after completing treatment
Study 23 (15)	Pulmonary or extrapulmonary TB, susceptible to RIF	Twice-weekly rifabutin plus INH in the continuation phase	At any time during the first 2 mo of treatment	Monthly during months 2–6 of treatment, then at 3, 6, 9, 12, 18, and 24 mo after completing treatment	Culture-positive treatment failure or recurrent TB	24 mo after completing treatment
Study 27 (13)	Smear-positive pulmonary TB, susceptible to RIF	Moxifloxacin vs. ethambutol (both in combination with INH, RIF, and PZA)	Within 7 d of starting TB treatment	Weeks 0, 2, 4, 6, and 8 and then monthly during the remainder of treatment	2-mo sputum culture status	Completion of TB therapy
Study 28 (14)	Smear-positive pulmonary TB, susceptible to INH and RIF	Moxifloxacin vs. INH (both in combination with RIF, PZA, and EMB)	Within 7 d of starting TB treatment	Weeks 0, 2, 4, 6, and 8 and then monthly during the remainder of treatment	2-mo sputum culture status	Completion of TB therapy

Definition of abbreviations: EMB = ethambutol; HIV = human immunodeficiency virus; INH, isoniazid; PZA = pyrazinamide; RIF = rifampin; TB = tuberculosis.